Quantitative analysis of HBV cccDNA from clinical specimens: Correlation with clinical and virological response during antiviral therapy

Journal of Viral Hepatitis

Volumn 14, Issue 1, 2007, Pages 55-63

  Bourne, E J ^a   Dienstag, J L ^b   Lopez, V A ^a   Sander, T J ^c   Longlet, J M ^c   Hall, J G ^c   Kwiatkowski, R W ^c   Wright, T ^d   Lai, C L ^e   Condreay, L D ^a  

^a GLAXOSMITHKLINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Third Wave Technologies Inc   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

cccDNA; Hepatitis B virus (HBV); Lamivudine

Indexed keywords

ALPHA INTERFERON; ASPARTIC ACID; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHIONINE; TYROSINE; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; DNA REPLICATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LIVER CELL; MONOTHERAPY; NEEDLE BIOPSY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SEROLOGY; TISSUE SPECIFICITY; TREATMENT RESPONSE; VIROLOGY;

ALANINE TRANSAMINASE; AMINO ACID MOTIFS; ANTIVIRAL AGENTS; BIOPSY, FINE-NEEDLE; DNA PROBES; DNA, CIRCULAR; DNA, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MUTATION; PILOT PROJECTS; VIRUS REPLICATION;

EID: 33845722719     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00775.x     Document Type: Article

References (34)

1. Seeff LB, Beebe GW, Hoofnagle JH et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987; 316: 965-970.
2. Rehermann B, Ferrari C, Pasquinelli C, Chisari F. The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108.
3. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986; 232: 477-484.
4. Summers J, Smith P, Horwich A. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol 1990; 64: 2819-2824.
5. Köck J, Schlicht H. Analysis of the earliest phases of hepadnaviral replication: genome repair after infectious entry into hepatocytes does not depend on the viral reverse transcriptase. J Virol 1993; 67: 4867-4874.
6. Stoll-Becker S, Repp R, Glebe D et al. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. J Virol 1997; 71: 5399-5407.
7. Yuen MF, Wong D, Sablon E et al. HBsAG seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39: 1694-1701.
8. Wong D, Yuen MF, Yuan HJ et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004; 40: 727-737.
9. Yuen MF, Wong D, Siu-Man Sum S et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1099-1103.
10. Hall J, Eis P, Law S et al. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc Natl Acad Sci USA 2000; 97: 8272-8277.
11. Singh M, Dicaire A, Krajden M, Wakil A, Sacks S. Rapid quantitation of hepatitis B virus (HBV) covalently-closed circular (ccc) and HBV total (T) DNA from liver using fluorescence-labeled oligonucleotide probes. Hepatology 2000; 32: 453a.
12. Sung JJY, Wong M-L, Bowden S et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-1897.
13. Dienstag J, Schiff E, Wright T et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.
14. Schiff E, Dienstag JL, Karayalcin S et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003; 38: 818-826.
15. Lai C-L, Chien R-N, Leung N et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
16. Leung NWY, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-1532.
17. Lyamichev V, Mast A, Hall J et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol 1999; 17: 292-296.
18. Lopez V, Bourne E, Lutz M, Condreay L. Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels. J Clin Microbiol 2002; 40: 1972-1976.
19. Seeger C, Mason W. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
20. Allen M, Gauthier J, Des Lauriers M et al. Two sensitive PCR-based methods for detection of hepatitis B variants associated with reduced susceptibility to lamivudine. J of Clin Microbiology 1999; 37: 3338-3347.
21. Zhang YY, Summer J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 2000; 74(11): 5257-5265.
22. Guo J, Zhou H, Liu C et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000; 74: 1495-1505.
23. Moraleda G, Saputelli J, Adrich C, Averett D, Condreay L, Mason W. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71: 9392-9399.
24. Zhu Y, Yamamoto T, Cullen J et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75: 311-322.
25. Pasquetto V, Wieland S, Uprichard S, Tripodi M, Chisari F. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 2002; 76: 5646-5653.
26. Robek M, Wieland S, Chisari F. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 2002; 76: 3570-3574.
27. Guidotti L, Morris A, Mendez H et al. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol 2002; 76: 2617-2621.
28. Heise T, Guidotti L, Chisari F. Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site. J Virol 2001; 75: 6874-6883.
29. Abdelhamed A, Kelley C, Miller T, Furman P, Isom H. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. J Virol 2002; 76: 8148-8160.
30. Zhang YZ, Zhang Bh, Theele D, Litwin S, Toll E, Summers J. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc Natl Acad Sci USA 2003; 100(21): 12373-12377.
31. Chien R-N, Liaw Y-F, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770-774.
32. Perrillo RP, Lai C-L, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-194.
33. Sette A, Oseroff C, Sidney J et al. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. J Immunol 2001; 166: 1389-1397.
34. Guidotti L, Chisari F. Noncytolytic control of viral infections by the innate and adaptive immune response. Ann Rev Immunol 2001; 19: 65-91.